Our Papers

Publications

Le Roux Ö, Everitt JI, and Counter CM. p53 dosage can impede KrasG12D- and KrasQ61R-mediated tumorigenesis. PLOS ONE 19(3):e0292189, 2024.

Le Roux Ö, Pershing NLK, Kaltenbrun E, Newman NJ, Everitt JI, Baldelli E, Pierobon M, Petricoin EF, and Counter CM. Genetically manipulating endogenous Kras levels and oncogenic mutations in vivo influences tissue patterning of murine tumorigenesis. eLife 11:e75715, 2022.

Li S, and Counter CM. An ultra-sensitive method to detect mutations in human RAS templates. Small GTPases 13:287-295, 2022.

Allen SR, Stewart RK, Rogers M, Ruiz IJ, Cohen E, Laederach A, Counter CM, Sawyer JK, and Fox DT. Distinct responses to rare codons in select Drosophila tissues. Elife 11:e76893, 2022.

Li S, and Counter CM. Non-canonical genomic driver mutations of urethane carcinogenesis. PLoS One 17:e0267147, 2021.

Klomp JE, Lee YS, Goodwin CM, Papke B, Klomp JA, Waters AM, Stalnecker CA, DeLiberty JM, Drizyte-Miller K, Yang R, Diehl JN, Yin HH, Pierobon M, Baldelli E, Ryan MB, Li S, Peterson J, Smith AR, Neal JT, McCormick AK, Kuo CJ, Counter CM, Petricoin EF 3rd, Cox AD, Bryant KL, and Der CJ. CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. Cell Rep 37:110060, 2021.

Adhikari H, Kattan WE, Kumar S, Zhou P, Hancock JF, and Counter CM. Oncogenic KRAS is dependent upon an EFR3A-PI4KA signaling axis for potent tumorigenic activity. Nat Commun 12: 5248, 2021.

Li S, and Counter CM. Signaling levels mold the RAS mutation tropism of urethane. eLife 10: e67172, 2021.

Adhikari H, and Counter CM. Using BioID to Characterize the RAS Interactome. Meth Mol Biol 2262:271–280, 2021.

Peterson J, Li S, Kaltenbrun E, Le Roux Ö, and Counter, CM. Expression of transgenes enriched in rare codons is enhanced by the MAPK pathway. Sci Rep 10: 22166, 2020.

Li S, MacAlpine DM, and Counter CM. Capturing the primordial Kras mutation initiating urethane carcinogenesis. Nat Commun 11: 1800, 2020.

Sawyer JK, Kabiri Z, Montague RA, Allen SR, Stewart R, Paramore SV, Cohen E, Zaribafzadeh H, Counter CM, and Fox DT Exploiting codon usage identifies intensity-specific modifiers of Ras/MAPK signaling in vivo. PLoS Genet, 16:e1009228, 2020.

Li S, Balmain A, and Counter CM. A model for RAS mutation patterns in cancers: finding the sweet spot.” Nat Rev Cancer 18: 767–77, 2018.

Fu J, Dang Y, Counter CM, and Liu Y. Codon usage regulates human KRAS expression at both transcriptional and translational levels. J Biol Chem 293: 17929–40, 2018.

Adhikari H, and Counter CM. Interrogating the protein interactomes of RAS isoforms identifies PIP5K1A as a KRAS-specific vulnerability. Nat Commun 9: 3646, 2018.

Xu MM, Casio M, Range DE, Sosa JA, and Counter CM. Copper chelation as targeted therapy in a mouse model of oncogenic BRAF-driven papillary thyroid cancer.” Clin Cancer Res 24: 4271–81, 2018.

Kabiri Z, Greicius G, Zaribafzadeh H, Hemmerich A, Counter CM, and Virshup DM. Wnt signaling suppresses MAPK-driven proliferation of intestinal stem cells. J Clin Invest 128: 3806–12, 2018.

Sasine JP, Himburg HA, Termini CM, Roos M, Tran E, Zhao L, Kan J, Li M, Zhang Y, de Barros S, Rao DS, Counter CM, and Chute JP.  Wild-type Kras expands and exhausts hematopoietic stem cells. JCI Insight 3: e98197, 2018.

Brady DC, Crowe MS, Greenberg DN, and Counter CM Copper chelation inhibits BRAFV600E-driven melanomagenesis and counters resistance to BRAFV600E and MEK1/2 inhibitors.” Cancer Res 77: 6240–52, 2017.

Anderson GR, Winter PA, Lin KH, Nussbaum DP, Cakir M, Stein EM, Soderquist RS, Crawford L, Leeds JC, Newcomb R, Stepp P, Yip C, Wardell SE, Tingley JP, Xu M, Ryan M, McCall SJ, McRee AJ, Counter CM, Der CJ, and Wood KC. A landscape of therapeutic cooperativity in KRAS mutant cancers reveals principles for controlling tumor evolution.” Cell Rep 20: 999–1015, 2017.

Ali M, Kaltenbrun E, Anderson, Stephens SJ, Arena S, Bardelli A, Counter CM, and Wood KC. Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance. Nat Commun 8: 15617, 2017.

Pershing NLK, Yang C-FJ, Xu MM, and Counter CM. Treatment with the nitric oxide synthase inhibitor L-NAME provides a survival advantage in a mouse model of Kras mutation-positive, non-small cell lung cancer. Oncotarget 7: 42385–92, 2016.

Weyandt JD, Carney JM, Pavlisko EN, Xu MM, and Counter CM. Isoform-specific effects of wild-type Ras genes on carcinogen-induced lung tumorigenesis in mice.” PLoS ONE 11: e0167205, 2016.

Weyandt JD, Lampson BL, Tang S, Mastrodomenico M, Cardona DM, and Counter CM. Wild-type Hras suppresses the earliest stages of tumorigenesis in a genetically engineered mouse model of pancreatic cancer. PLoS ONE, 10:e0140253, 2015.

Kashatus JA, Nascimento A, Myers LJ, Sher A, Byrne FL, Hoehn KL, Counter CM, and Kashatus DF . “Erk2 phosphorylation of Drp1 promotes mitochondrial fission and MAPK-driven tumor growth.” Mol Cell 57: 537–51, 2015.

Schook LB, Collares TV, Hu W, Liang Y, Rodrigues FM, Rund LA, Schachtschneider KM, Seixas FK, Sing K, and Counter CM. A genetic porcine model of cancer. PLoS ONE, 10: e0128864, 2015.

Huang L, and Counter CM. Reduced HRASG12V-driven tumorigenesis of cell lines expressing KRASC118S. PLoS ONE, 10: e0123918, 2015.

Pershing NLK, Lampson BL, Belsky JA, Kaltenbrun E, MacAlpine DM, and Counter CM. Rare codons capacitate Kras-driven de novo tumorigenesis. J Clin Invest, 125: 222-33, 2015.

Huang L, Carney J, Cardona DM, and Counter CM. Decreased tumorigenesis in mice with a Kras point mutation at C118. Nat Commun, 5: 5410, 2014.

Brady DC, Crowe MS, Turski ML, Hobbs GA, Yao X, Chaikuad A, Knapp S, Xiao K, Campbell SL, Thiele DJ, and Counter CM. Copper is required for oncogenic BRAF signaling and tumorigenesis.  Nature, 509: 492-6, 2014.

Yang S, and Counter CM. Cell cycle regulated phosphorylation of the telomere-associated protein TIN2. PLoS ONE, 8: e71697, 2013.

Lampson BL, Pershing NLK, Prinz JA, Lacsina JR, Marzluff WF, Nicchitta CV, MacAlpine DM, and Counter CM. Rare codons regulate KRas function. Curr Biol, 23: 70-9, 2013.

Stringer JR, and Counter CM. Snm1B interacts with PSF2. PLoS ONE, 7: e49626, 2012.

Lampson BL, Kendall SD, Ancrile BB, Morrison MM, Shealy MJ, Barrientos KS, Crowe MS, Kashatus DF, White RR, Gurley SB, Cardona DM, and Counter CM. Targeting eNOS in pancreatic cancer. Cancer Res, 72: 4472-82, 2012.

Yonekawa T, Yang S, and Counter CM. PinX1 localizes to telomeres and stabilizes TRF1 at mitosis. Mol Cell Biol, 32: 1387-95, 2012.

Turski ML, Brady DC, Kim HJ, Kim B-E, Nose Y, Counter CM, Winge DR, and Thiele DJ. A novel role for copper in Ras/mitogen-activated protein kinase signaling. Mol Cell Biol, 32: 1284-95, 2012.

Kashatus DF, and Counter CM. Breaking up is hard to do: RalA, mitochondria fission and cancer. Small GTPases, 2: 329-33, 2011.

Kashatus DF, Lim K-H, Brady DC, Pershing NLK, Cox AD, and Counter CM. RalA and RalBP1 regulate mitochondrial fission at mitosis. Nat Cell Biol, 13: 1108-15, 2011.

Kashatus DF, and Counter CM. A role for eNOS in oncogenic Ras-driven cancer. In Nitric oxide (NO) and cancer. Cancer Drug Disc Dev, 67: 23-38, 2010.

Zipfel PA, Brady DC, Kashatus DF, Ancrile BB, Tyler DS, and Counter CM. Ral activation promotes melanomagenesis. Oncogene 29: 4859-64, 2010

Vignola MJ, Kashatus DF, Taylor GA, Counter CM, and Valdivia RH. cPLA2 regulates the expression of type I interferons and intracellular immunity to Chlamydia trachomatis. J Biol Chem 285: 21625-35, 2010.

Issaq S, Lim K-H, and Counter CM. Sec5 and Exo84 foster oncogenic ras-mediated tumorigenesis.” Mol Cancer Res 8: 223–31, 2010.

Lim K-H, Brady DC, Kashatus DF, Ancrile BB, Der CJ, Cox AD, and Counter CM. Aurora-A phosphorylates, activates, and relocalizes the small GTPase RalA. Mol Cell Biol 30: 508–23, 2010.

Petersen TH, Hitchcock T, Muto A, Calle EA, Zhao L, Gong Z, Gui L, Dardik A, Bowles DE, Counter CM, and Niklason LE. Utility of telomerase-pot1 fusion protein in vascular tissue engineering.  Cell Transplant 19: 79–87, 2010.

O’Hayer KM, Brady DC, and Counter CM. “ELR+ CXC chemokines and oncogenic Ras-mediated tumorigenesis.” Carcinogenesis 30: 1841–47, 2009.

Kendellen MF, Barrientos KS, and Counter CM. POT1 association with TRF2 regulates telomere length. Mol Cell Biol 29: 5611–19, 2009.

Naini S, Etheridge KT, Adam SJ, Qualman SJ, Bentley RC, Counter CM, and Linardic CM . Defining the cooperative genetic changes that temporally drive alveolar rhabdomyosarcoma. Cancer Res 68: 9583–88, 2008.

Lee, Yi-Shan, Kian-Huat Lim, Xing Guo, Yoshiharu Kawaguchi, Yasheng Gao, Tomasa Barrientos, Peter Ordentlich, Xiao-Fan Wang, Christopher M. Counter, and Tso-Pang Yao. “The cytoplasmic deacetylase HDAC6 is required for efficient oncogenic tumorigenesis.” Cancer Res 68: 7561–69, 2008.

Lee Y-S, Lim K-H, Kawaguchi Y, Gao Y, Counter CM, and Yao T-P.  The cytoplasmic deacetylase HDAC6 is required for efficient oncogenic tumorigenesis.” Cancer Res 68: 7561–69, 2008.

Barrientos KS, Kendellen MF, Freibaum, BD, Armbruster BN, Etheridge KT, and Counter CM. Distinct functions of POT1 at telomeres. Mol Cell Biol 28: 5251–64, 2008.

Tomlinson RL, Abreu EB, Ziegler T, Ly H, Counter CM, Terns RM, and Terns MP. Telomerase reverse transcriptase is required for the localization of telomerase RNA to cajal bodies and telomeres in human cancer cells. Mol Biol Cell 19: 3793–3800, 2008.

Freibaum BD, and Counter CM. The protein hSnm1B is stabilized when bound to the telomere-binding protein TRF2. J Biol Chem 283: 23671–76, 2008.

Lim K-H, Ancrile BB, Kashatus DF, and Counter CM. Tumour maintenance is mediated by eNOS. Nature 452: 646–49, 2008.

Etheridge KT, Compton SA, Barrientos KS, Ozgur S, Griffith JD, and Counter CM. Tethering telomeric double- and single-stranded DNA-binding proteins inhibits telomere elongation. J Biol Chem 283: 6935–41, 2008.

Ancrile BB, O’Hayer KM, and Counter CM. Oncogenic ras-induced expression of cytokines: a new target of anti-cancer therapeutics. Mol Interv 8: 22–7, 2008.

Adam SJ, and Counter CM. A method to generate genetically defined tumors in pigs. Methods Enzymol 439: 39–51, 2008.

Linardic CM, and Counter CM. Genetic modeling of Ras-induced human rhabdomyosarcoma. Methods Enzymol 438: 419–27, 2008.

Schook LB, Kuzmuk K, Adam SJ, Rund L, Chen K, Rogatcheva M, Mazur M, Pollock C, and Counter CM. DNA-based animal models of human disease: from genotype to phenotype.” Dev Biol 132: 15–25, 2008.

Rogatcheva M, Fritz KL, Rund LA, Pollock CB, Beever JE, Counter CM, and Schook LB. Characterization of the porcine ATM gene: towards the generation of a novel non-murine animal model for Ataxia-Telangiectasia. Gene 405: 27–35, 2007.

Banik SSR, and Counter CM. From bread to bedside: What budding yeast has taught us about the immortalization of cancer cells. In: Yeast as a tool in cancer research. Nitiss JL & Heitman J (eds), Springer Press, pg 123-40, 2007

Ancrile BB, Lim K-H, and Counter CM. Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis. Genes Dev 21: 1714–19, 2007.

Linardic CM, Naini S, Qualman S, and Counter CM. The PAX3-FKHR fusion gene of rhabdomyosarcoma cooperates with loss of p16INK4A to promote bypass of cellular senescence. Cancer Res 67: 6691–99, 2007.

Adam SJ, Rund LA, Schook LB, and Counter CM. Genetic induction of tumorigenesis in swine. Oncogene 26: 1038–45, 2007.

Lim K-H, O’Hayer KM, Adam SJ, Kendall SD, Campbell PM, Der CJ, and Counter CM. Divergent roles for RalA and RalB in malignant growth of human pancreatic carcinoma cells. Curr Biol 16: 2385–94, 2006.

Lim K-H, and Counter CM. Comparison of the effects of Ras effector mutants and Ras effectors on transformed and tumorigenic growth of human and rodent cells. In: Proteins and Cell Regulation. Der CJ (ed), Springer Press, Ras Family GTPases, 4: 257-72, 2006.

Freibaum BD, and Counter CM. hSnm1B is a novel telomere-associated protein. J Biol Chem 281: 15033–36, 2006.

Kendall SD, Adam SJ, and Counter CM. Genetically engineered human cancer models utilizing mammalian transgene expression. Cell Cycle 5: 1074–79, 2006.

Baines AT, Lim K-H, Shields JM, Lambert JM, Counter CM, Der CJ, and Cox AD. Use of retrovirus expression of interfering RNA to determine the contribution of activated K-Ras and ras effector expression to human tumor cell growth. Methods Enzymol 407: 556–74, 2006.

O’Hayer KM, and Counter CM. A genetically defined normal human somatic cell system to study ras oncogenesis in vivo and in vitro. Methods Enzymol 407: 637–47, 2006.

Kendall SD, Linardic CM, Adam SJ, and Counter CM. A network of genetic events sufficient to convert normal human cells to a tumorigenic state. Cancer Res 65: 9824–28, 2005.

Lim K-H , and Counter CM. Reduction in the requirement of oncogenic Ras signaling to activation of PI3K/AKT pathway during tumor maintenance. Cancer Cell 8: 381–92, 2005.

Poh M, Boyer M, Solan A, Mitchell S, Pedrotty D, Banik SSR, McKee JA, Counter CM, and Niklason LE. Blood vessels engineered from human cells. Lancet 365: 2122–24, 2005.  Also see Lancet 366: 891–2, 2005

Lim K-H, Baines AT, Fiordalisi JJ, Shipitsin M, Feig LA, Cox AD, Der CJ, and Counter CM. Activation of RalA is critical for Ras-induced tumorigenesis of human cells. Cancer Cell 7: 533–45, 2005.

Linardic CM, Downie DL, Qualman S, Bentley RC, and Counter CM. Genetic modeling of human rhabdomyosarcoma. Cancer Res 65: 4490–95, 2005.

Veldman T, Etheridge KT, and Counter CM. Loss of hPot1 function leads to telomere instability and a cut-like phenotype. Curr Biol 14: 2264–70, 2004.

Banik SSR, and Counter CM. Characterization of interactions between PinX1 and human telomerase subunits hTERT and hTR. J Biol Chem 279: 51745–48, 2004.

Swanson KS, Mazur MJ, Vashisht K, Rund LA, Beever JE, Counter CM, and Schook LB. Genomics and clinical medicine: rationale for creating and effectively evaluating animal models. Exp Biol Med 229: 866–75, 2004.

Lim K-H, and Counter CM. Leveling the playing field. Mol Cell 15: 491–92, 2004.

Armbruster BN, Linardic CM, Veldman T, Bansal NP, Downie DL, and Counter CM. Rescue of an hTERT mutant defective in telomere elongation by fusion with hPot1. Mol Cell Biol 24: 3552–61, 2004.

Yeh E, Cunningham M, Arnold H, Chasse D, Monteith T, Ivaldi G, Hahn WC, Stukenberg PT, Shenolikar S, Uchida T, Counter CM, Nevins JR, Means AR & Sears R. A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat Cell Biol 6: 308–18, 2004.

Rogatcheva MM, Rund LA, Swanson KS, Marron BM, Beever JE, Counter CM, and Schook LB. Creating porcine biomedical models through recombineering. Comp Funct Genomics 5: 262–67, 2004.

Guo C, Armbruster BN, Price DT, and Counter CM. In vivo regulation of hTERT expression and telomerase activity by androgen. J Urol 170: 615–18, 2003.

McKee JA, Banik SSR, Boyer MJ, Hamad N, Lawson JH, Niklason LE, and Counter CM. Human arteries engineered in vitro. Embo Rep 4: 633–38, 2003.

Rich JN, Shi Q, Hjelmeland M, Cummings TJ, Kuan C-T, Bigner DD, Counter CM, and Wang X-F. Bone-related genes expressed in advanced malignancies induce invasion and metastasis in a genetically defined human cancer model. J Biol Chem 278: 15951–57, 2003.

Armbruster BN, Etheridge KT, Broccoli D, and Counter CM. Putative telomere-recruiting domain in the catalytic subunit of human telomerase. Mol Cell Biol 23: 3237–46, 2003.

Counter CM, Press W, and Compton CC. Telomere shortening in cultured autografts of patients with burns. Lancet 361: 1345–46, 2003.

Hamad NM, Banik SSR, and Counter CM. Mutational analysis defines a minimum level of telomerase activity required for tumourigenic growth of human cells. Oncogene 21: 7121–25, 2002.

Banik SSR, Guo C, Hamad NM, Shatkin-Margolis SN, Richardson DA, Smith AC, and Counter CM. C-terminal regions of the human telomerase catalytic subunit essential for in vivo enzyme activity. Mol Cell Biol 22: 6234–46, 2002.

Hamad NM, Elconin JE, Karnoub AE, Bai W, Rich JN, Abraham RT, Der CJ, and Counter CM. Distinct requirements for Ras oncogenesis in human versus mouse cells. Genes Dev 16: 2045–5, 2002.

Etheridge KT, Banik SSR, Armbruster BN, Zhu Y, Terns RM, Terns MP, and Counter CM. The nucleolar localization domain of the catalytic subunit of human telomerase. J Biol Chem 277: 24764–70, 2002.

Shi S, Gronthos S, Chen S, Reddi A, Counter CM, Robey PG, and Wang C-Y. Bone formation by human postnatal bone marrow stromal stem cells is enhanced by telomerase expression. Nat Biotechnol 20: 587–91, 2002.

Armbruster BN, Banik SSR, Guo C, Smith AC, and Counter CM. N-terminal domains of the human telomerase catalytic subunit required for enzyme activity in vivo. Mol Cell Biol 21: 7775–86, 2001.

Guo C, Geverd D, Liao R, Hamad N, Counter CM, and Price DT. Inhibition of telomerase is related to the life span and tumorigenicity of human prostate cancer cells. J Urol 166: 694–98, 2001.

Rich JN, Guo C, McLendon RE, Bigner DD, Wang X-F, and Counter CM. A genetically tractable model of human glioma formation. Cancer Res 61: 3556–60, 2001.

Banik SSR, and Counter CM. Telomerase and cancer. In: Hormone replacement therapy and cancer. Genazzani AR (ed), The Parthenon Publishing Group, 10-, 2001.

Hu PP-c, Shen X, Huang D, Liu Y, Counter CM, and Wang X-F. The MEK pathway is required for stimulation of p21(WAF1/CIP1) by transforming growth factor-beta. J Biol Chem 274: 35381–87, 1999.

Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, and Weinberg RA . Creation of human tumour cells with defined genetic elements. Nature 400: 464–68, 1999.

Xie Y, Counter CM, and Alani E Characterization of the repeat-tract instability and mutator phenotypes conferred by a Tn3 insertion in RFC1, the large subunit of the yeast clamp loader.” Genetics 151: 499–509, 1999.

Counter CM, Hahn WC, Wei W, Caddle SD, Beijersbergen RL, Lansdorp P, Sedivy JM & Weinberg RA. Dissociation among in vitro telomerase activity, telomere maintenance, and cellular immortalization.” Proc Natl Acad Sci USA 95: 14723–28, 1998.

Kolquist KA, Ellisen LW, Counter CM, Meyerson M, Tan LK, Weinberg RA, Haber DA, and Gerald WL. Expression of TERT in early premalignant lesions and a subset of cells in normal tissues. Nat Genet 19: 182–86, 1998.

Counter CM, Meyerson M, Ng Eaton E, Ellisen LW, Caddle SD, Haber DA & Weinberg RA. Telomerase activity is restored in human cells by ectopic expression of hTERT (hEST2), the catalytic subunit of telomerase. Oncogene 16: 1217–22, 1998.

Meyerson M, Counter CM, Ng Eaton E, Ellisen LW, Steiner P, Caddle SD, Ziaugra L, Beijersbergen RL, Davidoff MJ, Liu Q, Bacchetti S, Haber DA, and Weinberg RA. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 90: 785–95, 1997.

Counter CM, Meyerson M, Ng Eaton E, and Weinberg RA. The catalytic subunit of yeast telomerase. Proc Natl Acad Sci USA 94: 9202–7, 1997. 

Counter CM. The roles of telomeres and telomerase in cell life span. Mutat Res 366: 45–63, 1996.

Bacchetti S, and Counter CM. Telomeres and telomerase in human cancer. Int J Oncol 7: 423–32, 1995

Counter CM, Gupta J, Harley CB, Leber B, and Bacchetti S. Telomerase activity in normal leukocytes and in hematologic malignancies. Blood 85: 2315–20, 1995

Counter CM, Botelho FM, Wang P, Harley CB, and Bacchetti S. Stabilization of short telomeres and telomerase activity accompany immortalization of Epstein-Barr virus-transformed human B lymphocytes.” J Virol 68: 3410–14, 1994

Counter CM, Hirte HW, Bacchetti S, and Harley CB . Telomerase activity in human ovarian carcinoma. Proc Natl Acad Sci USA 91: 2900–4, 1994.

Harley CB, Prowse KR, West MD, Kim NW, Weinrich SL, Bacchetti S, Hirte HW, Counter CM, Greider CW, Wright WE, and Shay JW. Telomerase, cell immortality, and cancer. Cold Spring Harb Symp Quant Biol 59: 307–15, 1994

Greider CW, Autexier C, Avilion AA, Collins K, Harrington LA, Mantell LL, Prowse KR, Smith SK, Allsopp RC, Counter CM, Vaziri H, Bacchetti S & Harley CB. Telomeres and telomerase: Biochemistry and regulation in senescence and immortalization. In Chromosome, edited by J. S. Heslopharrison and R. B. Flavell, 115–25, 1993.

Harley CB, Vaziri H, Counter CM, and Allsopp R. The telomere hypothesis of cellular aging. Exp Gerontol 27: 375–82, 1992.

Counter CM, Avilion AA, Lefeuvre CE, Stewart NG, Greider CW, Harley CB, and Bacchetti S. Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. Embo J 11: 1921–29, 1991.

 

Papers Reviewed By:

Li S & Counter CM (2021) Signaling levels mold the RAS mutation tropism of urethane. Elife 10:e67172. [PMC8128437] 

  • Reviewed by: Butt Z & Prior I (2021) Tumor initiation: Danger zone. Elife 10:e69192.

 

Adhikari H & Counter CM (2018) Interrogating the protein interactomes of RAS isoforms identifies PIP5K1A as a KRAS-specific vulnerability. Nat Commun, 9:3646. [PMC6128905]

  • Reviewed by: East MP, Laitinen T & Asquith CRM (2020) PI5K1A: a potential target for cancers with KRAS or TP53 mutations. Nat Rev Drug Discov, 2020: Apr24.

 

Kashatus JA, Nascimento A, Myers LJ, Sher A, Byrne FL, Hoehn KL, Counter CM & Kashatus DF (2015) Erk2 phosphorylation of Drp1 promotes mitochondrial fission and MAPK-driven tumor growth. Mol Cell, 57:537-51. [PMC4393013]

  • Reviewed by: Cancer Discovery research watch (2015) MAPK-driven transformation requires DRP1-mediated mitochondrial division. Cancer Discov, 5:OF10

 

Pershing NLK, Lampson BL, Belsky JA, Kaltenbrun E, MacAlpine DM & Counter CM (2015) Rare codons capacitate Kras-driven de novo tumorigenesis. J Clin Invest, 125:222-33. [PMC4382256]

  • Reviewed by: JCI Editors (2015) Cracking the codon bias of KRAS in tumorigenesis. JCI Impact, January 2015:8.

 

Brady DC, Crowe MS, Turski ML, Hobbs GA, Yao X, Chaikuad A, Knapp S, Xiao K, Campbell SL, Thiele DJ & Counter CM (2014) Copper is required for oncogenic BRAF signaling and tumorigenesis. Nature, 509:492-6. [PMC4138975]

  • Reviewed by: Lokody I (2014) Inhibiting oncogenic BRAF signaling by copper depletion. Nat Rev Cancer, 14:384-5. Everts S (2014) Copper’s role in cancer. Chem Eng News, 92:23-4. Nature Editorial (2014) Copper rewired. Nature, 508:150.  Jarrett SG & D’Orazio JA (2014) Ctr1-ing BRAF signaling with copper. Pigment Cell Melanoma Res, 27:689-91.  Tsai KY (2014) Cupric needs: Copper is necessary for oncogenic BRAF signaling. NEJM Journal Watch, May 22, 2014.

 

Lampson BL, Pershing NLK*, Prinz JA*, Lacsina JR, Marzluff WF, Nicchitta CV, MacAlpine DM & Counter CM(2013) Rare codons regulate KRas function. Curr Biol, 23:70-9. [PMC3567844]

  • Reviewed by: Bodeman BO & White MA (2013) Ras GTPases: Codon bias holds KRas down but not out. Curr Biol 23:R17-9.

 

Lampson BL*, Kendall SD*, Ancrile BB*, Morrison MM, Shealy MJ, Barrientos KS, Crowe MS, Kashatus DF, White RR, Gurley SB, Cardona DM & Counter CM (2012) Targeting eNOS in pancreatic cancer. Cancer Res, 72:4472-82. [PMC3749841]

  • Reviewed by: Cancer Research editors (2012) Breaking Advances: Highlights from recent cancer literature. Targeting eNOS in pancreatic cancer: A long road ahead. Cancer Res, 72:8473-4.

 

Turski ML*, Brady DC*, Kim HJ, Kim B-E, Nose Y, Counter CM, Winge DR & Thiele DJ (2012) A novel role for copper in Ras/mitogen-activated protein kinase signaling. Mol Cell Biol, 32:1284-95. [PMC3302449]

  • Reviewed by: VanHook AM (2012) Editor’s choice: Copper as a kinase cofactor. Sci Signal, 5:ec84.

 

Kashatus DF, Lim K-H, Brady DC, Pershing NLK, Cox AD & Counter CM (2011) RalA and RalBP1 regulate mitochondrial fission at mitosis. Nat Cell Biol, 13:1108-15. [PMC3167028] (191 citations)

  • Reviewed by: Yamano K & Youle RJ (2011) Coupling mitochondrial and cell division. Nat Cell Biol, 13:1026-7.  Hurtley SM (2011) Editor’s choice, cell biology: Divide to survive. Science, 333:1681.  Maia AR & Maiato H (2011) Aurora mitochondrialis drive fission during mitosis. Dev Cell, 21:387-8.  Gough NR (2011) Editor’s choice, cell cycle: Ensuring adequate energy supply. Sci Signal, 4:ec273.

 

Lim K-H*, Ancrile BB*, Kashatus DF* & Counter CM (2008) eNOS mediates tumour maintenance. Nature, 452: 646-50. [PMC2688829]

  • Reviewed by: Novak K (2008) Follow you eNOS. Nat Rev Cancer, 8:322-3.  Larsen CJ (2008) Nitrosylation of Ras proteins is required to initiate and sustain tumoral growth. Bulletin du Cancer, 95:485.

 

Ancrile BB, Lim K-H & Counter CM (2007) Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis. Genes Dev, 21: 1714-9. [PMC1920165]

  • Reviewed by: Diaz-Flores E & Shannon K (2007) Targeting oncogenic Ras. Genes Dev, 21:1989-92.

 

Linardic CM, Downie DL, Qualman S, Bentley RC & Counter CM (2005) Genetic modeling of human rhabdomyosarcoma. Cancer Res, 65:4490-5. [PMID: 15930263]

  • Reviewed by: Cancer research highlights June 1, 2005: RMS model opens avenues for understanding malignancy mechanisms.

 

Poh M, Boyer M, Solan A, Mitchell S, Pedrotty D, Banik SSR, McKee JA, Counter CM & Niklason LE (2005) Blood vessels engineered from human cells. Lancet, 365:2122-4. [PMID: 15964449]

  • Reviewed by: Brey EM & Greisler HP (2005) Telomerase expression in somatic cells. Lancet. 365:2068-9.

 

Yeh E, Cunningham M, Arnold H, Chasse D, Monteith T, Ivaldi G, Hahn WC, Stukenberg PT, Shenolikar S, Uchida T, Counter CM, Nevins JR, Means AR & Sears R (2004) A signaling pathway controlling Myc degredation that impacts oncogenic transformation of human cells. Nat Cell Biol, 6:308-18. [PMID: 15048125]

  • Reviewed by: Dominguez-Sola D & Dalla-Favera R (2004) PINing down the c-Myc oncoprotein. Nat Cell Biol, 6:288-9.

 

McKee JA, Banik SSR, Boyer MJ, Hamad N, Lawson JH, Niklason LE* & Counter CM* (2003) Human arteries engineered in vitro. EMBO Rep, 4:633-8. [PMC1319197]

  • Reviewed by: Journal editors (2003) Immortalized cells help researchers grow human arteries. ASBMB Today 2:6-7.

 

Counter CM, Press W & Compton CC (2003) Telomere shortening in cultured autografts of patients with burns. Lancet, 361:1345-6. [PMID: 12711471]

  • Reviewed by: Navsaria HA & Rugg EL (2003) Telomere shortening: Significant for keratinocyte grafting? Lancet, 361:1316-7.  Journal editors (2003) Growing human skin in laboratory can prematurely age cells. ASBMB Today 2:8-9.

 

Hamad NM, Elconin JE, Karnoub AE, Bai W, Rich JN, Abraham RT, Der CJ & Counter CM (2002) Distinct requirements for Ras oncogenesis in human versus mouse cells. Genes Dev, 16:2045-57. [PMC186434]

  • Reviewed by: Kiberstis PA (2002) Editor’s choice: Steinbeck redux Science, 297:1447.  Boettner B & Van Aelst L (2002) The RASputin effect. Genes Dev, 16:2033-8.  Habeck M (2002) Of mice and men, and cancer research. Drug Disc Today, 7:981-2.  Habeck M (2002) Cancers with Ras may have an Archilles Heel. Lancet Oncol, 3:586.  Highlights in brief: Oncogenes (2002) Nat Rev Cancer 2:721.

 

Hahn WC*, Counter CM*, Lundberg AS, Beijersbergen RL, Brooks MW & Weinberg RA (1999) Creation of human tumor cells with defined genetic elements. Nature, 400:464-8. [PMID: 10440377]

  • Reviewed by: Weitzman JB & Yaniv M (1999) Rebuilding the road to cancer. Nature, 400:401-402.  Reed C (1999) A model tumor. Sci Am October 1999.

 

Counter CM*, Hahn WC*, Wei W, Caddle SD, Beijersbergen RL, Lansdorp P, Sedivy JM & Weinberg RA (1998) Dissociation between telomerase activity, telomere maintenance and cellular immortalization. Proc Natl Acad Sci USA, 95:14723-8. [PMC24516]

  • Reviewed by: Lustig AJ (1998) Crisis intervention: a role for telomerase. Proc Natl Acad Sci USA, 96:3339-3341.

 

Kolquist KA, Ellisen LW, Counter CM, Meyerson M, Tan LK, Weinberg RA, Haber DA & Gerald WL (1998) Expression of hTERT in early premalignant lesions and a subset of cells in normal tissues. Nat Genet, 19:182-6. [PMID: 9620778]

  • Reviewed by: (1998) Be fruitful and multiple. Nat Genet, 19:103-4.

 

Meyerson M*, Counter CM*, Ng Eaton E, Ellisen LW, Steiner P, Caddle SD, Ziaugra L, Beijersbergen RL, Davidoff MJ, Liu Q, Bacchetti S, Haber DA & Weinberg RA (1997) hEST2, the putative human telomerase catalytic subunit gene, is up-tegulated in tumor cells and during immortalization. Cell, 90:785-95. [PMID: 9288757]

  • Reviewed by:  Smaglik P (1999) Hot papers in telomerase. The Scientist, 13:14.  Kolberg R (1997) Nailing the gene for telomerase’s controller- twice. J NIH Res, 9:23-25.

 

Counter CM, Gupta J, Harley CB, Leber B & Bacchetti S (1995) Telomerase activity in normal leukocytes and in hematological malignancies. Blood, 85:2315-20. [PMID: 7727765]

  • Reviewed by: Young Kreeger K (1995) Hot papers- Telomere biology. The Scientist, 11:15.

 

Counter CM, Hirte HW, Bacchetti S & Harley CB (1994) Telomerase activity in human ovarian carcinoma. Proc Natl Acad Sci USA, 91:2900-4. [PMC43481]

  • Reviewed by: de Lange T (1994) Activation of telomerase in a human tumor. Proc Natl Acad Sci USA, 91:2882-5.  Borman S (1994) Study suggests telomerase inhibitors could be effective anticancer drugs. Chem Eng News, 72:42-4.  Rennie J (1994) Immortal’s enzyme. Sci Am, July:14-5.  Cancer cell’s fountain of youth. (1994) Biomed, May:319.  Hopkin K (1994) MTS1, telomerase may be new targets for cancer therapy. J NIH Res, 6:3838-42.